Toxin-Related Seizures

Emergency Medicine Clinics of North America

Volumn 29, Issue 1, 2011, Pages 125-139

  Sharma, Adhi N ^a,b   Hoffman, Robert J ^c  

^a Good Samaritan Hospital Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Benzodiazepines; GABA receptor complex; NMDA receptor; Toxin related seizures

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; COCAINE; DIAZEPAM; EXCITATORY AMINO ACID; GLUCOSE; GLUTAMATE RECEPTOR; HYDRAZINE; LORAZEPAM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PENTOBARBITAL; PHENCYCLIDINE; PHENYTOIN; POTASSIUM CHANNEL BLOCKING AGENT; PROPOFOL; PROPYLENE GLYCOL; PYRIDOXINE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL STIMULATING AGENT; THEOPHYLLINE; UNINDEXED DRUG;

AIRWAY; BOLUS INJECTION; BRAIN NERVE CELL; BREATHING; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; GENERAL ANESTHESIA; GLUCOSE BLOOD LEVEL; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYDRAZINE POISONING; INCIDENCE; INTOXICATION; ION CURRENT; LOADING DRUG DOSE; MOTOR ACTIVITY; NEUROMUSCULAR BLOCKING; NEUROTRANSMITTER RELEASE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SEIZURE; THEOPHYLLINE TOXICITY; TOXIN RELATED SEIZURE;

EID: 78649408073     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2010.08.011     Document Type: Review

References (92)

1. Neundorfer B., Meyer-Wahl L., Meyer J.G., et al. Wien Klin Wochenschr 1978, 90(21):765-772. [in German].
2. Granger N., Convers P., Beauchet O., et al. Rev Neurol (Paris) 2002, 158(11):1088-1095. [in French].
3. Vespignani H., Legras B., Weber M., et al. Rev Electroencephalogr Neurophysiol Clin 1981, 11(3-4):524-530. [in French].
4. Pesola G.R., Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med 2002, 22(3):235-239.
5. Pascual-Sedano B., Iranzo A., Marti-Fabregas J., et al. Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Arch Neurol 1999, 56(5):609-612.
6. Kunisaki T.A., Augenstein W.L. Drug- and toxin-induced seizures. Emerg Med Clin North Am 1994, 12(4):1027-1056.
7. Panganiban L.R., Makalinao I.R., Corte-Maramba N.P. Rhabdomyolysis in isoniazid poisoning. J Toxicol Clin Toxicol 2001, 39(2):143-151.
8. Shah B.R., Santucci K., Sinert R., et al. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995, 95(5):700-704.
9. Belson M.G., Kelley T.R. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med 2002, 23(3):223-230.
10. Balit C.R., Lynch C.N., Isbister G.K. Bupropion poisoning: a case series. Med J Aust 2003, 178(2):61-63.
11. Whyte I.M., Dawson A.H., Buckley N.A. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003, 96(5):369-374.
12. Blumer J., Strong J.M., Atkinson A.J. The convulsant potency of lidocaine and its N-dealkylated metabolites. J Pharmacol Exp Ther 1973, 186(1):31-36.
13. Spivey W.H. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992, 14(2):292-305.
14. Gueye P.N., Hoffman J.R., Taboulet P., et al. Empiric use of flumazenil in comatose patients: limited applicability of criteria to define low risk. Ann Emerg Med 1996, 27(6):730-735.
15. van Gelder N.M., Sherwin A.L. Metabolic parameters of epilepsy: adjuncts to established antiepileptic drug therapy. Neurochem Res 2003, 28(2):353-365.
16. Sherwin A.L. Neuroactive amino acids in focally epileptic human brain: a review. Neurochem Res 1999, 24(11):1387-1395.
17. Ben Ari Y. Cell death and synaptic reorganizations produced by seizures. Epilepsia 2001, 42(Suppl 3):5-7.
18. Ronne-Engstrom E., Hillered L., Flink R., et al. Intracerebral microdialysis of extracellular amino acids in the human epileptic focus. J Cereb Blood Flow Metab 1992, 12(5):873-876.
19. Carlson H., Ronne-Engstrom E., Ungerstedt U., et al. Seizure related elevations of extracellular amino acids in human focal epilepsy. Neurosci Lett 1992, 140(1):30-32.
20. Buckley N.A., Dawson A.H., Whyte I.M., et al. Relative toxicity of benzodiazepines in overdose. BMJ 1995, 310(6974):219-221.
21. Ferenci P., Grimm G. Benzodiazepine antagonist in the treatment of human hepatic encephalopathy. Adv Exp Med Biol 1990, 272:255-265.
22. Yager J.Y., Armstrong E.A., Miyashita H., et al. Prolonged neonatal seizures exacerbate hypoxic-ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release. Dev Neurosci 2002, 24(5):367-381.
23. Kulik A., Trapp S., Ballanyi K. Ischemia but not anoxia evokes vesicular and Ca(2+)-independent glutamate release in the dorsal vagal complex in vitro. J Neurophysiol 2000, 83(5):2905-2915.
24. Clausen T., Zauner A., Levasseur J.E., et al. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res 2001, 908(1):35-48.
25. Vecsei L., Dibo G., Kiss C. Neurotoxins and neurodegenerative disorders. Neurotoxicology 1998, 19(4-5):511-514.
26. Vornov J.J. Toxic NMDA-receptor activation occurs during recovery in a tissue culture model of ischemia. J Neurochem 1995, 65(4):1681-1691.
27. Chapman A.G., Graham J.L., Patel S., et al. Anticonvulsant activity of two orally active competitive N-methyl-D-aspartate antagonists, CGP 37849 and CGP 39551, against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio. Epilepsia 1991, 32(4):578-587.
28. Patel S., Chapman A.G., Graham J.L., et al. Anticonvulsant activity of the NMDA antagonists, D(-)4-(3-phosphonopropyl) piperazine-2-carboxylic acid (D-CPP) and D(-)(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy. Epilepsy Res 1990, 7(1):3-10.
29. Messenheimer J.A. Lamotrigine. Epilepsia 1995, 36(Suppl 2):S87-S94.
30. Rockhold R.W. Glutamatergic involvement in psychomotor stimulant action. Prog Drug Res 1998, 50:155-192.
31. Peris J., Dunwiddie T.V. Inhibitory neuromodulation of release of amino acid neurotransmitters. Alcohol Drug Res 1985, 6(4):253-264.
32. Blanchet G., Carpentier P., Lallement G., et al. Ann Pharm Fr 1994, 52(1):11-24. [in French].
33. Nordt S.P., Chew G. Acute lindane poisoning in three children. J Emerg Med 2000, 18(1):51-53.
34. Glenn G.M., Krober M.S., Kelly P., et al. Pyridoxine as therapy in theophylline-induced seizures. Vet Hum Toxicol 1995, 37(4):342-345.
35. Tanaka I., Ito Y., Hiraga Y., et al. Arerugi 1996, 45(10):1098-1105. [in Japanese].
36. Gregus Z., Klaassen C. Mechanisms of toxicity. Casarett and Doull's toxicology: the basic science of poisons 1996, 35-75. McGraw-Hill Companies, New York. C. Klaassen (Ed.).
37. During M.J., Spencer D.D. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993, 341(8861):1607-1610.
38. Berman R.F., Fredholm B.B., Aden U., et al. Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. Brain Res 2000, 872(1-2):44-53.
39. Eldridge F.L., Paydarfar D., Scott S.C., et al. Role of endogenous adenosine in recurrent generalized seizures. Exp Neurol 1989, 103(2):179-185.
40. Kelsey M.C., Grossberg G.T. Safety and efficacy of caffeine-augmented ECT in elderly depressives: a retrospective study. J Geriatr Psychiatry Neurol 1995, 8(3):168-172.
41. Lurie S.N., Coffey C.E. Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. J Clin Psychiatry 1990, 51(4):154-157.
42. Leentjens A.F., van den Broek W.W., Kusuma A., et al. Facilitation of ECT by intravenous administration of theophylline. Convuls Ther 1996, 12(4):232-237.
43. Shannon M., Maher T. Anticonvulsant effects of intracerebroventricular adenocard in theophylline-induced seizures. Ann Emerg Med 1995, 26(1):65-68.
44. Huber A., Padrun V., Deglon N., et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A 2001, 98(13):7611-7616.
45. Dunn D.W., Parekh H.U. Theophylline and status epilepticus in children. Neuropediatrics 1991, 22(1):24-26.
46. Goldberg M.J., Spector R., Miller G. Phenobarbital improves survival in theophylline-intoxicated rabbits. J Toxicol Clin Toxicol 1986, 24(3):203-211.
47. Blake K.V., Massey K.L., Hendeles L., et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988, 17(10):1024-1028.
48. Taboulet P., Michard F., Muszynski J., et al. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. J Toxicol Clin Toxicol 1995, 33(3):205-211.
49. Graudins A., Dowsett R.P., Liddle C. The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med (Fremantle) 2002, 14(4):440-446.
50. Jacqz-Aigrain E., Bennasr S., Desplanques L., et al. Arch Pediatr 1994, 1(1):14-19. [in French].
51. Sharma A.N., Hexdall A.H., Chang E.K., et al. Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. Am J Emerg Med 2003, 21(3):212-215.
52. Radovanovic D., Meier P.J., Guirguis M., et al. Dose-dependent toxicity of diphenhydramine overdose. Hum Exp Toxicol 2000, 19(9):489-495.
53. Spiller H.A., Carlisle R.D. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002, 40(1):81-90.
54. Tsai J., Chern T.L., Hu S.C., et al. The clinical implication of theophylline intoxication in the emergency department. Hum Exp Toxicol 1994, 13(10):651-657.
55. Spiegel D.A., Dexter F., Warner D.S., et al. Central nervous system toxicity of local anesthetic mixtures in the rat. Anesth Analg 1992, 75(6):922-928.
56. Olson K.R., Kearney T.E., Dyer J.E., et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993, 11(6):565-568.
57. Boehnert M.T., Lovejoy F.H. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985, 313(8):474-479.
58. Leutmezer F., Schernthaner C., Lurger S., et al. Electrocardiographic changes at the onset of epileptic seizures. Epilepsia 2003, 44(3):348-354.
59. Nelson L.S., Hoffman R.S. Mexiletine overdose producing status epilepticus without cardiovascular abnormalities. J Toxicol Clin Toxicol 1994, 32(6):731-736.
60. Patel M.M., Tsutaoka B.T., Banerji S., et al. ED utilization of computed tomography in a poisoned population. Am J Emerg Med 2002, 20(3):212-217.
61. Earnest M.P., Feldman H., Marx J.A., et al. Intracranial lesions shown by CT scans in 259 cases of first alcohol-related seizures. Neurology 1988, 38(10):1561-1565.
62. Zagnoni P.G., Albano C. Psychostimulants and epilepsy. Epilepsia 2002, 43(Suppl. 2):28-31.
63. Osuide G., Wambebe C., Ngur D. Studies on the pharmacology of d-amphetamine on maximal electroconvulsive seizure in young chicks. Psychopharmacology (Berl) 1983, 81(2):119-121.
64. Kleinrok Z., Czuczwar S.J., Kozicka M. Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 1980, 21(5):519-529.
65. De Sarro G.B., De Sarro A. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology 1993, 32(1):52-58.
66. Nevins M.E., Arnolde S.M. A comparison of the anticonvulsant effects of competitive and non-competitive antagonists of the N-methyl-D-aspartate receptor. Brain Res 1989, 503(1):1-4.
67. Munn R.I., Farrell K. Failure to recognize status epilepticus in a paralysed patient. Can J Neurol Sci 1993, 20(3):234-236.
68. Lowenstein D.H., Aminoff M.J., Simon R.P. Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients. Neurology 1988, 38(3):395-400.
69. Leppik I.E., Derivan A.T., Homan R.W., et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249(11):1452-1454.
70. Chamberlain J.M., Altieri M.A., Futterman C., et al. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997, 13(2):92-94.
71. Miller J., Robinson A., Percy A.K. Acute isoniazid poisoning in childhood. Am J Dis Child 1980, 134(3):290-292.
72. Saad S.F., el-Masry A.M., Scott P.M. Influence of certain anticonvulsants on the concentration of -aminobutyric acid in the cerebral hemispheres of mice. Eur J Pharmacol 1972, 17(3):386-392.
73. Orser B.A., Bertlik M., Wang L.Y., et al. Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br J Pharmacol 1995, 116(2):1761-1768.
74. Rossetti A.O., Milligan T.A., Vulliémoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2010, [Epub ahead of print].
75. Rossetti A.O., Reichhart M.D., Schaller M.D., et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45(7):757-763.
76. Van Ness P.C. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia 1990, 31(1):61-67.
77. Rashkin M.C., Youngs C., Penovich P. Pentobarbital treatment of refractory status epilepticus. Neurology 1987, 37(3):500-503.
78. Kaneda M., Wakamori M., Akaike N. GABA-induced chloride current in rat isolated Purkinje cells. Am J Physiol 1989, 256(6 Pt 1):C1153-C1159.
79. Miller L.G., Deutsch S.I., Greenblatt D.J., et al. Acute barbiturate administration increases benzodiazepine receptor binding in vivo. Psychopharmacology (Berl) 1988, 96(3):385-390.
80. Akaike N., Tokutomi N., Ikemoto Y. Augmentation of GABA-induced current in frog sensory neurons by pentobarbital. Am J Physiol 1990, 258(3 Pt 1):C452-C460.
81. Cawley M.J. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001, 21(9):1140-1144.
82. Reynolds H.N., Teiken P., Regan M.E., et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000, 28(5):1631-1634.
83. Brown L.A., Levin G.M. Role of propofol in refractory status epilepticus. Ann Pharmacother 1998, 32(10):1053-1059.
84. Prasad A., Worrall B.B., Bertram E.H., et al. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001, 42(3):380-386.
85. Kang T.M. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002, 36(9):1453-1456.
86. Kofke W.A., Young R.S., Davis P., et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology 1989, 71(5):653-659.
87. Murao K., Shingu K., Tsushima K., et al. The anticonvulsant effects of volatile anesthetics on penicillin-induced status epilepticus in cats. Anesth Analg 2000, 90(1):142-147.
88. Okamoto M., Rosenberg H.C., Boisse N.R. Evaluation of anticonvulsants in barbiturate withdrawal. J Pharmacol Exp Ther 1977, 202(2):479-489.
89. Chance J.F. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 1991, 20:520-522. [see comments].
90. Callaham M., Schumaker H., Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther 1988, 245(1):216-220.
91. Derlet R.W., Albertson T.E., Tharratt R.S. Lidocaine potentiation of cocaine toxicity. Ann Emerg Med 1991, 20(2):135-138.
92. Bowyer K., Glasser S.P. Chloral hydrate overdose and cardiac arrhythmias. Chest 1980, 77(2):232-235.